General Information of Drug (ID:
DR0843) |
Drug Name |
Ibrutinib
|
Synonyms |
Ibrutinib; Ibrutinib (PCI-32765); PCI 32765; PCI-32765; PCI-32765 (Ibrutinib); PCI32765; IMBRUVICA; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; 1X70OSD4VX; 936563-96-1; A1-01649; CHEBI:76612; CRA-032765; UNII-1X70OSD4VX
|
Indication |
Mantle cell lymphoma
[ICD11: 2A85]
|
Approved
|
[1]
|
Structure |
|
|
3D MOL
|
2D MOL
|
Pharmaceutical Properties |
Molecular Weight |
440.5 |
Topological Polar Surface Area |
99.2 |
Heavy Atom Count |
33 |
Rotatable Bond Count |
5 |
Hydrogen Bond Donor Count |
1 |
Hydrogen Bond Acceptor Count |
6 |
Cross-matching ID |
- PubChem CID
- 24821094
- PubChem SID
-
49837088
; 57132050
; 123051065
; 124898784
; 124898785
; 136940589
; 136961336
; 137472671
; 152258295
; 160647134
; 162202692
; 163312254
; 163679284
; 164045821
; 164193915
; 165245631
; 171572071
; 172919350
; 174007139
; 175267389
; 176250273
; 178103494
; 184611713
; 184816969
; 189025882
; 198993428
; 215784879
; 223375297
; 223485070
; 223600477
; 223685684
; 223704724
; 224184328
; 226558356
; 242585660
; 247523488
; 249736825
; 251971042
; 252088605
; 252110183
; 252160516
; 252215999
; 252451849
- ChEBI ID
-
- CAS Number
-
- TTD Drug ID
- D09KTS
- Formula
- C25H24N6O2
- Canonical SMILES
- C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
- InChI
- 1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
- InChIKey
- XYFPWWZEPKGCCK-GOSISDBHSA-N
|
|
|
|
|
|
|
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.